CD8型
细胞毒性T细胞
T细胞
癌症研究
免疫学
细胞疗法
白细胞介素2
生物
干细胞
化学
细胞生物学
免疫系统
生物化学
体外
作者
Masao Hashimoto,Suresh S. Ramalingam,Rafi Ahmed
标识
DOI:10.1016/j.trecan.2023.11.008
摘要
Abstract
There is considerable interest in developing more effective programmed cell death (PD)-1 combination therapies against cancer. One major obstacle to these efforts is a dysfunctional/exhausted state of CD8 T cells, which PD-1 monotherapy is not able to overcome. Recent studies have highlighted that PD-1+ T cell factor (TCF)-1+ stem-like CD8 T cells are not fate locked into the exhaustion program and their differentiation trajectory can be changed by interleukin (IL)-2 signals. Modifying the CD8 T cell exhaustion program and generating better effectors from stem-like CD8 T cells by IL-2 form the fundamental immunological basis for combining IL-2 with PD-1 therapy. Many versions of IL-2-based products are being tested and each product should be carefully evaluated for its ability to modulate dysfunctional states of anti-tumor CD8 T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI